The AHA’s Target BP initiative is a movement to increase blood pressure control among adults living with hypertension in the United States.
The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...
A positive response to treatment for pediatric obesity has enduring health benefits into young adulthood, according to study findings.
A medication often used to treat high blood pressure and prevent migraines was associated with a reduction in ischemic stroke risk among women using the drug for migraine prevention, according to a ...
Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...
Common drugs taken by up to 10million Americans may lower the risk of stroke in women with chronic migraines, a study from ...
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), supporting endpo ...
Tectonic Therapeutic is a biotechnology company focused on the development of novel therapies for cardiovascular diseases, particularly those involving pulmonary hypertension and heart failure. Its ...
The trial's safety results were reassuring, with no serious adverse events or significant changes in vital signs, physical exams, or safety laboratory values post-administration of TX45. Transient ...
Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone ...
Advances in medical treatment for cardiovascular disease, a leading cause of death in the U.S., have helped patients live longer. But a new report finds that risk factors that lead to heart disease ...
Cardiovascular disease is the number one cause of death in the United States, at a cost of about 700,000 lives per year. For ...